Study S003343

A PHASE 1, OPEN-LABEL, SINGLE-DOSE, PARALLEL-GROUP STUDY TO EVALUATE THE PHARMACOKINETICS, SAFETY AND TOLERABILITY OF PF-08653944 IN ADULTS WITH AND WITHOUT VARYING DEGREES OF HEPATIC IMPAIRMENT

ClinicalTrials.gov record

Registration

Registration: NCT07519135
Study type: INTERVENTIONAL
Phase: PHASE1
Masking: NONE
Status: RECRUITING
Enrollment: 26
Start: 2026-04-15
Primary completion: 2027-07-09
Lead sponsor: Pfizer
Conditions: Healthy
Interventions: DRUG:PF-08653944
Results posted: FALSE
Individual participant data sharing: NO
Secondary identifiers: OTHER:MET097-25-105

Registered primary outcomes

Pharmacokinetics (PK): Maximum observed plasma concentration (Cmax) of PF-08653944 [Day 1 pre-dose through approximately 11 Weeks after last dose of study intervention.]
PK: Area under the plasma concentration (AUC) of PF-08653944 [Day 1 pre-dose through approximately 11 Weeks after last dose of study intervention.]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.